MX2024005391A - Métodos para tratar cánceres y potenciar la eficacia de anticuerpos biespecíficos para gprc5dxcd3. - Google Patents
Métodos para tratar cánceres y potenciar la eficacia de anticuerpos biespecíficos para gprc5dxcd3.Info
- Publication number
- MX2024005391A MX2024005391A MX2024005391A MX2024005391A MX2024005391A MX 2024005391 A MX2024005391 A MX 2024005391A MX 2024005391 A MX2024005391 A MX 2024005391A MX 2024005391 A MX2024005391 A MX 2024005391A MX 2024005391 A MX2024005391 A MX 2024005391A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- bispecific antibodies
- treating cancers
- enhancing efficacy
- gprc5dxcd3 bispecific
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163275356P | 2021-11-03 | 2021-11-03 | |
| PCT/US2022/079144 WO2023081704A1 (en) | 2021-11-03 | 2022-11-02 | Methods of treating cancers and enhancing efficacy of gprc5dxcd3 bispecific antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024005391A true MX2024005391A (es) | 2024-08-06 |
Family
ID=86242157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024005391A MX2024005391A (es) | 2021-11-03 | 2022-11-02 | Métodos para tratar cánceres y potenciar la eficacia de anticuerpos biespecíficos para gprc5dxcd3. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230295292A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4426436A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024540053A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240099371A (cg-RX-API-DMAC10.html) |
| CN (1) | CN118369114A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022382978A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3237352A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL312513A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024005391A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023081704A1 (cg-RX-API-DMAC10.html) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019220368A1 (en) * | 2018-05-16 | 2019-11-21 | Janssen Biotech, Inc. | Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy |
| US20220411508A1 (en) * | 2019-09-09 | 2022-12-29 | The Regents Of The University Of California | Compositions and methods for making and using multispecific antibodies |
| WO2021195513A1 (en) * | 2020-03-27 | 2021-09-30 | Novartis Ag | Bispecific combination therapy for treating proliferative diseases and autoimmune disorders |
-
2022
- 2022-11-02 AU AU2022382978A patent/AU2022382978A1/en active Pending
- 2022-11-02 CA CA3237352A patent/CA3237352A1/en active Pending
- 2022-11-02 CN CN202280073849.4A patent/CN118369114A/zh active Pending
- 2022-11-02 US US18/052,172 patent/US20230295292A1/en active Pending
- 2022-11-02 WO PCT/US2022/079144 patent/WO2023081704A1/en not_active Ceased
- 2022-11-02 JP JP2024525208A patent/JP2024540053A/ja active Pending
- 2022-11-02 IL IL312513A patent/IL312513A/en unknown
- 2022-11-02 KR KR1020247018007A patent/KR20240099371A/ko active Pending
- 2022-11-02 EP EP22891007.1A patent/EP4426436A4/en active Pending
- 2022-11-02 MX MX2024005391A patent/MX2024005391A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230295292A1 (en) | 2023-09-21 |
| AU2022382978A1 (en) | 2024-06-20 |
| WO2023081704A1 (en) | 2023-05-11 |
| KR20240099371A (ko) | 2024-06-28 |
| EP4426436A1 (en) | 2024-09-11 |
| JP2024540053A (ja) | 2024-10-31 |
| IL312513A (en) | 2024-07-01 |
| CA3237352A1 (en) | 2023-05-11 |
| CN118369114A (zh) | 2024-07-19 |
| EP4426436A4 (en) | 2025-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024005392A (es) | Métodos para tratar cánceres y potenciar la eficacia de anticuerpos biespecíficos para bcmaxcd3. | |
| PH12020551932A1 (en) | Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics | |
| CY1123977T1 (el) | Anti-pd-1 και anti-lag3 αντισωματα για την θεραπεια του καρκινου | |
| CL2020003071A1 (es) | Proteínas de unión multiespecíficas y mejoras con estas | |
| AR124882A1 (es) | Anticuerpo triespecífico dirigido a bcma, gprc5d, y cd3 | |
| CL2018000502A1 (es) | Anticuerpos biespecíficos para pd1 y tim3 útiles como inmunomoduladores o en el tratamiento del cáncer. | |
| PE20210288A1 (es) | Anti-cd25 para el agotamiento de celulas tumorales especificas | |
| MY200602A (en) | Antibodies against tim3 and uses thereof | |
| MX2022014166A (es) | Metodos para tratar el mieloma multiple. | |
| CL2018003407A1 (es) | Anticuerdos anti-pd-1, método para producir el mismo y método para usar el mismo. | |
| MX2020014158A (es) | Anticuerpos anti proteína de muerte programada 1 (pd-1) y usos de estos. | |
| ZA202206993B (en) | Anti-lilrb1 antibody and uses thereof | |
| AR106365A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
| PE20120902A1 (es) | Anticuerpos anti-egfl7 humanizados | |
| MX2021010877A (es) | Moleculas de union a cumulo de diferenciacion 3 (cd3). | |
| CL2022000950A1 (es) | Métodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes. | |
| MX2021012767A (es) | Metodos para tratar el cancer de prostata con un anticuerpo anti-psma/cd3. | |
| MX2022010161A (es) | Proteínas biespecíficas anti-her2 diseñadas. | |
| MX2022014254A (es) | Anticuerpos anti-hemojuvelina (hjv) para tratar mielofibrosis. | |
| ZA202213434B (en) | Anti-lilrb1 antibody and uses thereof | |
| CO2023009626A2 (es) | Métodos de tratamiento del cáncer usando anticuerpos anti-tigit en combinación con anticuerpos anti-pd1 | |
| BR112022008652A2 (pt) | Anticorpos biespecíficos hla-a2/wt1 x cd3, uso de um anticorpo biespecífico, método para tratar câncer em um indivíduo, kit e invenção | |
| EA202090565A1 (ru) | Композиции и способы лечения диффузной в-крупноклеточной лимфомы | |
| BR112021020873A2 (pt) | Métodos para tratamento de câncer renal com um anticorpo anti-psma/cd3 | |
| MX2020008769A (es) | Agentes anticuerpos anti-cd25. |